Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JNJ-80948543 |
Synonyms | |
Therapy Description |
JNJ-80948543 is an antibody that targets an undisclosed tumor-associated antigen (TAA) and the T-cell antigen CD3, potentially resulting in activation of cytotoxic T-lymphocytes (CTLs) and tumor cell killing (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JNJ-80948543 | JNJ 80948543|JNJ80948543 | CD3 Antibody 99 | JNJ-80948543 is an antibody that targets an undisclosed tumor-associated antigen (TAA) and the T-cell antigen CD3, potentially resulting in activation of cytotoxic T-lymphocytes (CTLs) and tumor cell killing (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05424822 | Phase I | JNJ-80948543 | A Study of JNJ-80948543, a T Cell Redirecting Antibody, in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | POL | ISR | FRA | DNK | AUS | 2 |